U 101 - TCM Biotech International
Alternative Names: U-101 - TCM Biotech InternationalLatest Information Update: 31 Oct 2025
At a glance
- Originator TCM Biotech International
- Class Urinary anti-infective agents
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Urinary tract infections
Most Recent Events
- 01 Oct 2025 TCM Biotech International plans to launch U 101 (TCM Biotech International pipeline, October 2025)
- 31 Dec 2023 TCM Biotech International has patent protection for U 101 in Europe (TCM Biotech International website, October 2025)
- 31 Dec 2022 TCM Biotech International has patent protection for U 101 in South Korea and Japan (TCM Biotech International website, October 2025)